Related Experiment Video
Updated: Mar 29, 2026

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
Published on: September 17, 2019
Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead
Everardo González-González1, Mario Moisés Alvarez1,2,3,4, Alan Roberto Márquez-Ipiña1
1a Centro de Biotecnología-FEMSA, Tecnológico de Monterrey , Monterrey , Nuevo León , Mexico.
Abstract:
The 2014 Ebola outbreak, the largest recorded, took us largely unprepared, with no available vaccine or specific treatment. In this context, the World Health Organization declared that the humanitarian use of experimental therapies against Ebola Virus (EBOV) is ethical. In particular, an experimental treatment consisting of a cocktail of three monoclonal antibodies (mAbs) produced in tobacco plants and specifically directed to the EBOV glycoprotein (GP) was tested in humans, apparently with good results. Several mAbs with high affinity to the GP have been described. This review discusses our current knowledge on this topic. Particular emphasis is devoted to those mAbs that have been assayed in animal models or humans as possible therapies against Ebola. Engineering aspects and challenges for the production of anti-Ebola mAbs are also briefly discussed; current platforms for the design and production of full-length mAbs are cumbersome and costly.
Related Concept Videos
Cross-reactivity
Anthelminthic Agents
Inhibitors of Viral Protein Synthesis
Targeted Cancer Therapies
There are several types of targeted therapies against...
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Tumor Immunotherapy

